Rewriting Pain Management: How Opioid Policies Are Evolving
Pain management remains a central component of recovery following injury, surgery, and other acute medical conditions. Opioids such as oxycodone, hydrocodone, morphine, and tramadol continue to play an important role in treating moderate to severe pain. However, concerns regarding misuse, dependence, overdose, and long-term use have led to significant changes in prescribing practices over the past decade. [1,2]
Today, healthcare providers must balance effective pain control with patient safety. As a result, opioid prescribing policies have evolved through new prescribing limits, enhanced documentation requirements, and broader use of Prescription Drug Monitoring Programs (PDMPs). These changes continue to shape pain management across healthcare, including workers' compensation. [2,3]
Shorter Prescriptions for Acute Pain
One of the most significant changes in opioid policy has been the implementation of limits on initial opioid prescriptions for acute pain.
Many states now restrict opioid prescriptions to three to seven days for acute conditions, depending on the patient's clinical circumstances and risk factors. [3]
Acute pain typically occurs following:
Injuries
Surgical procedures
Dental work
Other short-term conditions expected to improve with healing
Research suggests that most patients require only a few days of opioid therapy to effectively manage acute pain. Longer prescriptions may increase the likelihood of prolonged opioid use and dependence. [4]
These prescribing limits encourage providers to:
Reassess patients more frequently
Monitor recovery progress
Consider nonopioid alternatives when appropriate
While these limits have improved safety, some concerns remain. Certain injuries and postoperative complications may require longer treatment durations, highlighting the importance of allowing providers flexibility when clinically justified.
Greater Oversight for High-Risk Prescribing
In addition to prescription duration limits, many states now require additional documentation when prescribing opioids at higher doses or for extended periods.
These requirements often apply when:
Daily opioid doses exceed specific thresholds
Patients have a history of substance use disorder
Opioids are prescribed alongside benzodiazepines
Long-term opioid therapy is being considered [5]
Enhanced documentation may include:
Clinical justification for treatment
Assessment of patient risk factors
Treatment goals
Informed consent discussions
Monitoring and follow-up plans
These requirements support responsible prescribing practices while ensuring treatment decisions are aligned with patient safety standards.
The Growing Role of Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs (PDMPs) have become one of the most important tools in opioid stewardship.
PDMPs are statewide electronic databases that allow providers and pharmacists to review a patient's-controlled substance prescription history before prescribing or dispensing medications. [6]
Today, PDMPs operate in all 50 states, the District of Columbia, and several U.S. territories, with many states requiring providers to review the system before issuing opioid prescriptions. [7]
PDMPs help identify potential concerns such as:
Multiple prescriptions from different providers
High cumulative opioid doses
Dangerous drug combinations
Potential misuse or diversion
Access to this information helps providers make more informed prescribing decisions while reducing medication-related risks.
What This Means for Recovery
The evolution of opioid policy reflects a broader shift toward responsible pain management.
While opioids remain an important treatment option for certain patients, providers are increasingly encouraged to:
Use the lowest effective dose
Limit duration when appropriate
Reevaluate treatment regularly
Consider nonopioid therapies as part of a comprehensive recovery plan [2]
For workers' compensation patients, these practices may help reduce the risk of long-term dependence while supporting safer recovery and return-to-work outcomes.
Employers, payers, and healthcare providers also benefit from clearer prescribing expectations, stronger monitoring practices, and improved documentation standards.
By Merna Khalil
PharmD Candidate (P4)
For questions, e-mail pharmd@prodigyrx.com
References
1. Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. Updated 2024. Accessed April 15, 2026. Understanding the Opioid Overdose Epidemic | Overdose Prevention | CDC
2. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain, United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
3. National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic. Updated 2024. Accessed April 15, 2026. https://www.ncsl.org/health/opioid-policy-fellows
4. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use. MMWR Morb Mortal Wkly Rep. 2017;66(10):265-269. https://www.cdc.gov/mmwr/volumes/66/wr/mm6610a1.htm
5. Federation of State Medical Boards. Guidelines for the chronic use of opioid analgesics. Updated 2023. Accessed April 15, 2026. https://www.fsmb.org
6. Prescription Drug Monitoring Program Training and Technical Assistance Center. PDMP overview and national status report. Updated 2024. Accessed April 15, 2026. https://www.pdmpassist.org
7. Substance Abuse and Mental Health Services Administration. Prescription drug monitoring programs: a guide for healthcare providers. Updated 2023. Accessed April 15, 2026. https://www.samhsa.gov
